{"id":"NCT05081167","sponsor":"Relmada Therapeutics, Inc.","briefTitle":"A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-02","primaryCompletion":"2022-09-13","completion":"2022-09-14","firstPosted":"2021-10-18","resultsPosted":"2024-03-26","lastUpdate":"2024-03-26"},"enrollment":232,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"REL-1017","otherNames":["esmethadone"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"REL-1017","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.","primaryOutcome":{"measure":"Change in the MADRS10 Total Score From Baseline to Day 28","timeFrame":"Day 28","effectByArm":[{"arm":"REL-1017 25 mg","deltaMin":-14.8,"sd":12.4},{"arm":"Placebo","deltaMin":-13.9,"sd":10.8}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://reliancestudies.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":116},"commonTop":["Headache","Nausea","Dizziness","COVID-19","Fatigue"]}}